背景 Dihydropyrimidine 脱氢酶( DPD ),涉及5氟尿嘧啶( 5-FU )的分解代谢的关键酶,是关于这研究的 .The 目的是探索在 dihydropyrimidine 脱氢酶基因( DPYD )和在中国 population.Methods 与基于氟尿嘧啶的辅助化疗对待的胃的癌症病人的临床的结果的多型性之间的协会的 5-FU 的功效和毒性的 pharmacogenetic 研究的吸引人的候选人有气体的 362 个病人
Background Dihydropyrimidine dehydrogenase (DPD), a key enzyme involved in the catabolism of 5-fluorouracil (5-FU), is the attractive candidate for pharmacogenetic research on efficacies and toxicities of 5-FU. The aim of this study is to explore the association between polymorphisms of dihydropyrimidine dehydrogenase gene (DPYD) and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in the Chinese population.